Excerpt from Novo Nordisk financial report issued on January 31, 2024
“In January 2024, Novo Nordisk initiated a phase 1 trial with a next-generation oral small molecule CB1 receptor blocker INV-347. The trial is investigating safety, tolerability and pharmacokinetics of INV-347. INV-202, also an oral small molecule CB1 receptor blocker, is currently in phase 2 for diabetic kidney disease. In the second half of 2023, Novo Nordisk initiated a phase 2 trial in people with obesity with INV-202. Both INV-202 trials are expected to complete in the second half of 2025. All trials are conducted by Inversago Pharma, which was acquired by Novo Nordisk in 2023.”
